13F Holdings
中文EN

AMGN AMGEN INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 318154 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.2%
TTM net income YoY34.1%
TTM EPS YoY33.4%
Revenue 3-yr CAGR13.2%
Net income 3-yr CAGR7.5%

Margins

Gross margin70.9%
Operating margin32.4%
Net margin24.1%
FCF margin24.6%
EBITDA margin39.4%

Returns

ROE78.4%
ROA10.1%
ROIC (approx.)19.5%
Asset turnover0.42x

Leverage & solvency

Liabilities / assets85.1%
Debt / equity3.76x
Current ratio1.48x
Interest coverage4.78x

Cash quality & payout

Operating cash flow / net income1.28x
Accruals ratio-2.8%
Payout ratio57.1%
Capex / revenue6.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$36.75B$33.42B$28.19B$26.32B$25.98B
Cost of revenue$12.04B$12.86B$8.45B$6.41B$6.45B
Gross profit$24.71B$20.57B$19.74B$19.92B$19.52B
R&D expense$7.27B$5.96B$4.78B$4.43B$4.82B
SG&A expense$7.05B$7.10B$6.18B$5.41B$5.37B
Operating income$9.08B$7.26B$7.90B$9.57B$7.64B
Interest expense$2.75B$3.15B$2.88B$1.41B$1.20B
Pretax income$8.98B$4.61B$7.86B$7.35B$6.70B
Income tax$1.26B$519.00M$1.14B$794.00M$808.00M
Net income$7.71B$4.09B$6.72B$6.55B$5.89B
EBITDA$14.25B$12.85B$11.97B$12.98B$11.04B
EPS (basic)14.337.6212.5612.1810.34
EPS (diluted)14.237.5612.4912.1110.28
Dividends declared per share9.669.138.647.957.22
Weighted avg. shares (diluted)542.00M541.00M538.00M541.00M573.00M
Balance sheet
Cash & equivalents$9.13B$11.97B$10.94B$7.63B$7.99B
Short-term investments——$0$1.68B$48.00M
Receivables$9.57B$6.78B$7.27B$5.56B$4.89B
Inventory$6.22B$7.00B$9.52B$4.93B$4.09B
Current assets$29.06B$29.03B$30.33B$22.19B$19.39B
PP&E, net$7.91B$6.54B$5.94B$5.43B$5.18B
Goodwill$18.68B$18.64B$18.63B$15.53B$14.89B
Intangibles$22.28B$27.70B$32.64B$16.08B$15.18B
Total assets$90.59B$91.84B$97.15B$65.12B$61.16B
Current liabilities$25.49B$23.10B$18.39B$15.69B$12.18B
Short-term debt$4.60B$3.55B$1.44B$1.59B$87.00M
Long-term debt$50.01B$56.55B$63.17B$37.35B$33.22B
Total debt$54.60B$60.10B$64.61B$38.95B$33.31B
Total liabilities$81.93B$85.96B$90.92B$61.46B$54.47B
Shareholders' equity$8.66B$5.88B$6.23B$3.66B$6.70B
Net debt$45.48B$48.13B$53.67B$31.32B$25.32B
Shares outstanding538.80M536.90M535.40M534.00M558.30M
Cash flow statement
Operating cash flow$9.96B$11.49B$8.47B$9.72B$9.26B
Capital expenditure$1.86B$1.10B$1.11B$936.00M$880.00M
Free cash flow$8.10B$10.39B$7.36B$8.79B$8.38B
Investing cash flow-$1.94B-$1.05B-$26.20B-$6.04B$733.00M
Financing cash flow-$10.86B-$9.41B$21.05B-$4.04B-$8.27B
Depreciation & amortization$5.17B$5.59B$4.07B$3.42B$3.40B
Stock-based compensation$494.00M$530.00M$431.00M$401.00M$341.00M
Dividends paid$5.12B$4.83B$4.56B$4.20B$4.01B
Share buybacks$0$200.00M$0$6.36B$4.97B

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.